ArticleFrontiers in oncology2026
Results of applying the 9th edition TNM classification in the staging assessment of nasopharyngeal carcinoma: first data in Vietnam.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate stage changes when applying the 9th edition of the TNM classification instead of the 8th edition in Vietnamese patients with nasopharyngeal carcinoma. Method: A cross-sectional descriptive study was conducted in newly diagnosed patients with nasopharyngeal carcinoma treated at the Department of Head and Neck Radiation Oncology of Vietnam National Cancer Hospital (K Hospital) from January 2025 to December 2025. Results: The study included 555 patients, with a mean age of 51.8 ± 13.5 years. The male-to-female ratio was 2.53/1. Most patients had non-keratinizing squamous cell carcinoma, undifferentiated subtype, accounting for 99.3%. According to the 8th edition of the TNM classification, the distributions of T stage, N stage were 25,4% T1, 25,9% T2, 23,4% T3, 24,3% T4; 13,3% N0, 37,8% N1, 33,0% N2, 15,9% N3; and Stage III-IVA accounting for 64.1%. When reassessed using the 9th edition, there were 6 patients experienced changes in N stage, and 88.3% of patients changed overall stage. This reclassification affected treatment decisions, with 1 patient having their standard treatment approach modified based on the 9th edition of the TNM classification. Conclusion: The 9th edition of the TNM classification introduces several changes compared with the 8th edition, potentially improving prognostic assessment and patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.